Effect of VSL#3 Probiotic in a Patient with Glycogen Storage Disease Type Ia and Irritable Bowel Disease-like Disease
- 163 Downloads
Gut Inflammatory bowel disease (IBD) is a group of chronic gastrointestinal disorders characterised by relapsing and remitting inflammation of the gastrointestinal tract. The two most common types of IBDs are ulcerative colitis and Crohn’s disease. Patients with glycogen storage disease (GSD) type Ia present with gastrointestinal symptoms such as recurrent abdominal pain, bloating and changes in stool form or frequency, which is clinically difficult to distinguish from IBD. We report the case of a 36-year-old man with GSD type Ia and IBD-like disease. A commercial probiotic (VSL#3®) was chosen as a nutritional supplement treatment because of its high content of microbial species and strains. Three different tests were performed: normal-dose, no-dose and half-dose tests. The study periods for the normal-dose, no-dose and half-dose tests were 4 weeks from the treatment initiation, 72 h from the end of the previous period and 4 weeks to 6 months after the end of the 72-h period, respectively. When the probiotic treatment was stopped, he experienced several symptoms similar to those before the start of the treatment. The intestinal symptoms were less severe with the half-dose nutritional supplement treatment than with no treatment. Probiotics may reduce the number of irritable gut episodes and improve the patient’s well-being and overall quality of life. More studies are needed to determine whether the improvement in more severe cases of GSD is due mainly to changes in the composition of the gut microbiota, as in this patient.
KeywordsProbiotics Glycogen storage disease type Ia Inflammatory bowel disease Gut microbiota
We thank the staff of the Endocrinology and Nutrition consultation of the University of Santiago de Compostela Hospital Complex for their help in conducting the anthropometric measures.
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.
Compliance with Ethical Standards
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2008.
The authors declare that there are no competing interests regarding the publication of this paper.
Right to privacy and informed consent. The authors have obtained informed consent of the patients and/or subjects referred to in the manuscript.
- 1.Chen YT (2001) Glycogen storage diseases. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic & molecular bases of inherited disease. McGraw-Hill, New York, pp 1521–1551Google Scholar
- 9.Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Doré J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, MetaHIT Consortium, Bork P, Ehrlich SD, Wang J (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464(7285):59–65. https://doi.org/10.1038/nature08821 CrossRefGoogle Scholar
- 12.Brahe LK, Chatelier EL, Prifti E, Brahe LK, Chatelier EL, Prifti E, Pons N, Kennedy S, Hansen T, Pedersen O, Astrup A, Ehrlich SD, Larsen LH (2015) Specific gut microbiota features and metabolic markers in postmenopausal women with obesity. Nutr Diab 5(6):e159. https://doi.org/10.1038/nutd.2015.9 CrossRefGoogle Scholar
- 13.Larsen N, Vogensen FK, van den Berg FWJ, Nielsen DS, Andreasen AS, Pedersen BK, Al-Soud WA, Sørensen SJ, Hansen LH, Jakobsen M (2010) Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One 5(2):e9085. https://doi.org/10.1371/journal.pone.0009085 CrossRefGoogle Scholar
- 15.Scaldaferri F, Gerardi V, Lopetuso LR, Zompo FD, Mangiola F, Boškoski I, Bruno G, Petito V, Laterza L, Cammarota G, Gaetani E, Sgambato A, Gasbarrini A (2013) Gut microbial flora, prebiotics, and probiotics in IBD: their current usage and utility. Biomed Res Int 2013:435268–435269. https://doi.org/10.1155/2013/435268 CrossRefGoogle Scholar
- 18.Abayasekara LM, Perera J, Chandrasekharan V, Gnanam VS, Udunuwara NA, Liyanage DS, Bulathsinhala NE, Adikary S, Aluthmuhandiram JVS, Thanaseelan CS, Tharmakulasingam DP, Karunakaran T, Ilango J (2017) Detection of bacterial pathogens from clinical specimens using conventional microbial culture and 16S metagenomics: a comparative study. BMC Infect Dis 17(1):631. https://doi.org/10.1186/s12879-017-2727-8 CrossRefGoogle Scholar
- 23.Buss C, Valle-Tovo C, Miozzo S, Alves de Mattos A (2014) Probiotics and synbiotics mayimprove liver aminotransferases levels in non-alcoholic fatty liver disease patients. Ann Hepatol 13(5):482–488Google Scholar
- 24.Kirpich IA, Solovieva NV, Leikhter SN, Shidakova NA, Lebedeva OV, Sidorov PI, Bazhukova TA, Soloviev AG, Barve SS, McClain CJ, Cave M (2008) Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study. Alcohol 42(8):675–682. https://doi.org/10.1016/j.alcohol.2008.08.006 CrossRefGoogle Scholar
- 25.Khalesi S, Johnson DW, Campbell K, Williams S, Fenning A, Saluja S, Irwin C (2017) Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. Eur J Nutr. https://doi.org/10.1007/s00394-017-1568-y
- 27.Conroy S, Hale MF, Cross SS, Swallow K, Sidhu RH, Sargur R, Lobo AJ (2017) Unrestricted faecal calprotectin testing performs poorly in the diagnosis of inflammatory bowel disease in patients in primary care. J Clin Pathol. https://doi.org/10.1136/jclinpath-2017-204506